Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SALI-10
- Development stage
- Phase 3
- Lead developer
- Ostia Sciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SALI-10 is a next-generation oral care probiotic developed from the *Streptococcus salivarius* (SALI-10) strain. This probiotic is designed to support oral and respiratory health by maintaining a healthy oral microbiome. The unique feature of this strain is its production of Salivaricin 10, the world’s first phosphorylated lantibiotic (a type of bacteriocin), which will be evaluated in clinical trials for its ability to promote beneficial microbial balance and support immune function in the mouth and upper respiratory tract. The product has been formulated as lozenges for slow dissolution at the site of action in the mouth. Clinical trials are set to begin soon, with commercialization targeted for early 2026[6][8].
- Brand names
- SALI-10SALI10SALI 10
- Other names
- Streptococcus salivarius SALI-10Salivaricin 10 probiotic strainSalivaricin10 probiotic strainSalivaricin-10 probiotic strain
02
Targets
Lipid II
Beyond the preview
Go deeper on SALI-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SALI-10.